Drugs / Epaxal
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01360970 | Sep 2009 → May 2011 | — | Lars Rombo | Completed | No outcome recorded |
| Phase 2 | NCT01405677 | Jun 2004 → Apr 2012 | hepatitis A virus infection | Crucell Holland BV | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01307436 | Mar 2007 → Jul 2013 | hepatitis A virus infection | Crucell Holland BV | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01926860 | Aug 2013 → Oct 2019 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPAXAL | “The present study explores whether a simultaneously given hepatitis A vaccine (Epaxal) will have an impact on the immune response to PCV13 (pneumococcal conjugate vaccine;...” NCT01926860 ↗ |
| Known as | Hepatitis A vaccine | “The present study explores whether a simultaneously given hepatitis A vaccine (Epaxal) will have an impact on the immune response to PCV13 (pneumococcal conjugate vaccine;...” NCT01926860 ↗ |
| Modality | Vaccine | “Virosomal Hepatitis A Vaccine” NCT01405677 ↗ |
| Route | Intramuscular | “0.5 ml im (Epaxal” NCT01360970 ↗ |